Do analysts recommend INCR or CALC?

CalciMedica has a consensus target price of $50.00, suggesting a potential upside of 2,425.25%. Given CalciMedica's stronger consensus rating and higher probable upside, analysts clearly believe CalciMedica is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CalciMedica 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Is INCR or CALC more profitable?

InterCure's return on equity of 0.00% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A CalciMedica N/A -863.40% -155.24%

Does the media refer more to INCR or CALC?

In the previous week, CalciMedica had 3 more articles in the media than InterCure. MarketBeat recorded 6 mentions for CalciMedica and 3 mentions for InterCure. CalciMedica's average media sentiment score of 0.79 beat InterCure's score of 0.62 indicating that CalciMedica is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InterCure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CalciMedica 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RYM or CALC?

CalciMedica has a consensus target price of $50.00, indicating a potential upside of 2,425.25%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CalciMedica 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Is RYM or CALC more profitable?

CalciMedica has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets RYTHM -6.20% -12.57% -2.60% CalciMedica N/A -863.40% -155.24%

Is CALC or SCYX more profitable?

CalciMedica has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -44.15% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -155.24% SCYNEXIS -41.79% -44.15% -32.61%

Does the media favor CALC or SCYX?

In the previous week, CalciMedica had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 6 mentions for CalciMedica and 5 mentions for SCYNEXIS. CalciMedica's average media sentiment score of 0.79 beat SCYNEXIS's score of 0.50 indicating that CalciMedica is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CalciMedica 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SCYNEXIS 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, CALC or CLNN?

Clene has higher revenue and earnings than CalciMedica. Clene is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CalciMedica N/A N/A -$29.56M -$6.80 N/A Clene $200K 229.37 -$26.17M -$3.50 N/A

Is CALC or CLNN more profitable?

CalciMedica has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -155.24% Clene -20,063.96% N/A -137.04%

Does the media refer more to CALC or CLNN?

In the previous week, CalciMedica had 4 more articles in the media than Clene. MarketBeat recorded 6 mentions for CalciMedica and 2 mentions for Clene. Clene's average media sentiment score of 0.94 beat CalciMedica's score of 0.79 indicating that Clene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CalciMedica 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CALC or AGFY?

CalciMedica presently has a consensus target price of $50.00, suggesting a potential upside of 2,425.25%. Given CalciMedica's stronger consensus rating and higher possible upside, equities analysts clearly believe CalciMedica is more favorable than Agrify. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CALC or AGFY more profitable?

CalciMedica has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Agrify's return on equity of -185.90% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -155.24% Agrify -424.11% -185.90% -72.67%

CalciMedica (CALC) Competitors

$1.98 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.01 +0.03 (+1.52%)

As of 04:39 AM Eastern

Compare

CALC vs. INCR, RYM, SCYX, CLNN, and AGFY

Should you buy CalciMedica stock or one of its competitors? CalciMedica's main competitors and comparable companies include InterCure (INCR), RYTHM (RYM), SCYNEXIS (SCYX), Clene (CLNN), and Agrify (AGFY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CalciMedica compare to InterCure?

InterCure (NASDAQ:INCR) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

InterCure has higher revenue and earnings than CalciMedica. CalciMedica is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.72	-$10.37M	$0.15	34.40
CalciMedica	N/A	N/A	-$29.56M	-$6.80	N/A

8.3% of InterCure shares are owned by institutional investors. 28.3% of CalciMedica shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, CalciMedica had 3 more articles in the media than InterCure. MarketBeat recorded 6 mentions for CalciMedica and 3 mentions for InterCure. CalciMedica's average media sentiment score of 0.79 beat InterCure's score of 0.62 indicating that CalciMedica is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InterCure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CalciMedica	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InterCure's return on equity of 0.00% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
CalciMedica	N/A	-863.40%	-155.24%

CalciMedica has a consensus target price of $50.00, suggesting a potential upside of 2,425.25%. Given CalciMedica's stronger consensus rating and higher probable upside, analysts clearly believe CalciMedica is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CalciMedica	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

InterCure has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, CalciMedica has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

Summary

InterCure beats CalciMedica on 8 of the 14 factors compared between the two stocks.

How does CalciMedica compare to RYTHM?

RYTHM (NASDAQ:RYM) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

RYTHM has a beta of 9.44, meaning that its stock price is 844% more volatile than the broader market. Comparatively, CalciMedica has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

CalciMedica has lower revenue, but higher earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28M	2.74	-$33.26M	-$10.53	N/A
CalciMedica	N/A	N/A	-$29.56M	-$6.80	N/A

CalciMedica has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
CalciMedica	N/A	-863.40%	-155.24%

CalciMedica has a consensus target price of $50.00, indicating a potential upside of 2,425.25%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CalciMedica	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

6.0% of RYTHM shares are held by institutional investors. 3.5% of RYTHM shares are held by insiders. Comparatively, 28.3% of CalciMedica shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, CalciMedica had 5 more articles in the media than RYTHM. MarketBeat recorded 6 mentions for CalciMedica and 1 mentions for RYTHM. RYTHM's average media sentiment score of 1.87 beat CalciMedica's score of 0.79 indicating that RYTHM is being referred to more favorably in the media.

Company	Overall Sentiment
RYTHM	Very Positive
CalciMedica	Positive

Summary

CalciMedica beats RYTHM on 9 of the 15 factors compared between the two stocks.

How does CalciMedica compare to SCYNEXIS?

CalciMedica (NASDAQ:CALC) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

SCYNEXIS has higher revenue and earnings than CalciMedica. SCYNEXIS is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$6.80	N/A
SCYNEXIS	$20.60M	2.34	-$8.61M	-$2.09	N/A

In the previous week, CalciMedica had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 6 mentions for CalciMedica and 5 mentions for SCYNEXIS. CalciMedica's average media sentiment score of 0.79 beat SCYNEXIS's score of 0.50 indicating that CalciMedica is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CalciMedica	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CalciMedica currently has a consensus price target of $50.00, indicating a potential upside of 2,425.25%. SCYNEXIS has a consensus price target of $33.00, indicating a potential upside of 581.82%. Given CalciMedica's higher possible upside, equities research analysts plainly believe CalciMedica is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

CalciMedica has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -44.15% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-155.24%
SCYNEXIS	-41.79%	-44.15%	-32.61%

54.4% of SCYNEXIS shares are owned by institutional investors. 28.3% of CalciMedica shares are owned by company insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CalciMedica has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Summary

SCYNEXIS beats CalciMedica on 8 of the 14 factors compared between the two stocks.

How does CalciMedica compare to Clene?

CalciMedica (NASDAQ:CALC) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

23.3% of Clene shares are held by institutional investors. 28.3% of CalciMedica shares are held by company insiders. Comparatively, 28.3% of Clene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, CalciMedica had 4 more articles in the media than Clene. MarketBeat recorded 6 mentions for CalciMedica and 2 mentions for Clene. Clene's average media sentiment score of 0.94 beat CalciMedica's score of 0.79 indicating that Clene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CalciMedica	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Clene has higher revenue and earnings than CalciMedica. Clene is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$6.80	N/A
Clene	$200K	229.37	-$26.17M	-$3.50	N/A

CalciMedica presently has a consensus price target of $50.00, suggesting a potential upside of 2,425.25%. Clene has a consensus price target of $34.00, suggesting a potential upside of 852.38%. Given CalciMedica's higher possible upside, research analysts plainly believe CalciMedica is more favorable than Clene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

CalciMedica has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Clene has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

CalciMedica has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-155.24%
Clene	-20,063.96%	N/A	-137.04%

Summary

Clene beats CalciMedica on 11 of the 15 factors compared between the two stocks.

How does CalciMedica compare to Agrify?

CalciMedica (NASDAQ:CALC) and Agrify (NASDAQ:AGFY) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

6.0% of Agrify shares are held by institutional investors. 28.3% of CalciMedica shares are held by company insiders. Comparatively, 2.2% of Agrify shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CalciMedica has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Agrify's return on equity of -185.90% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-155.24%
Agrify	-424.11%	-185.90%	-72.67%

CalciMedica has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Agrify has a beta of 9.96, indicating that its stock price is 896% more volatile than the broader market.

In the previous week, CalciMedica had 6 more articles in the media than Agrify. MarketBeat recorded 6 mentions for CalciMedica and 0 mentions for Agrify. CalciMedica's average media sentiment score of 0.79 beat Agrify's score of 0.00 indicating that CalciMedica is being referred to more favorably in the media.

Company	Overall Sentiment
CalciMedica	Positive
Agrify	Neutral

CalciMedica has higher earnings, but lower revenue than Agrify. Agrify is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$6.80	N/A
Agrify	$12.26M	3.54	-$41.75M	-$22.65	N/A

CalciMedica presently has a consensus target price of $50.00, suggesting a potential upside of 2,425.25%. Given CalciMedica's stronger consensus rating and higher possible upside, equities analysts clearly believe CalciMedica is more favorable than Agrify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

CalciMedica beats Agrify on 10 of the 15 factors compared between the two stocks.

Get CalciMedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CALC vs. The Competition

Export

Metric	CalciMedica	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.52M	$12.45B	$7.15B	$12.84B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-0.29	799.76	275.25	25.35
Price / Sales	N/A	759.43	641.16	90.72
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	-0.86	10.42	10.42	6.21
Net Income	-$29.56M	$2.85B	$3.50B	$358.54M
7 Day Performance	-8.76%	-3.56%	-3.27%	-2.35%
1 Month Performance	-41.34%	0.53%	-0.82%	-3.37%
1 Year Performance	-87.51%	3.62%	23.56%	8.81%

CalciMedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CALC CalciMedica	4.3149 of 5 stars	$1.98 flat	$50.00 +2,425.3%	-87.5%	$13.52M	N/A	N/A	30	Analyst Downgrade Short Interest Decrease Gap Up
INCR InterCure	1.3598 of 5 stars	$5.25 -2.6%	N/A	-34.3%	$57.44M	$78.47M	35.00	350
RYM RYTHM	0.8886 of 5 stars	$23.64 -0.8%	N/A	N/A	$51.51M	$51.01M	N/A	140	Gap Down High Trading Volume
SCYX SCYNEXIS	3.1354 of 5 stars	$4.91 -4.7%	$33.00 +572.1%	-46.0%	$48.85M	$20.60M	N/A	60	Gap Down
CLNN Clene	2.0586 of 5 stars	$3.72 +2.8%	$33.25 +793.8%	-38.4%	$47.80M	$197K	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CALC) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CalciMedica (CALC) Competitors

CALC vs. INCR, RYM, SCYX, CLNN, and AGFY

How does CalciMedica compare to InterCure?

Summary

How does CalciMedica compare to RYTHM?

Summary

How does CalciMedica compare to SCYNEXIS?

Summary

How does CalciMedica compare to Clene?

Summary

How does CalciMedica compare to Agrify?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC vs. The Competition

CalciMedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CalciMedica (CALC) Competitors

CALC vs. INCR, RYM, SCYX, CLNN, and AGFY

How does CalciMedica compare to InterCure?

Which has stronger valuation and earnings, INCR or CALC?

Do institutionals & insiders hold more shares of INCR or CALC?

Does the media refer more to INCR or CALC?

Is INCR or CALC more profitable?

Do analysts recommend INCR or CALC?

Which has more risk and volatility, INCR or CALC?

Summary

How does CalciMedica compare to RYTHM?

Which has more volatility & risk, RYM or CALC?

Which has preferable valuation and earnings, RYM or CALC?

Is RYM or CALC more profitable?

Do analysts rate RYM or CALC?

Do institutionals and insiders have more ownership in RYM or CALC?

Does the media refer more to RYM or CALC?

Summary

How does CalciMedica compare to SCYNEXIS?

Which has higher valuation and earnings, CALC or SCYX?

Does the media favor CALC or SCYX?

Do analysts rate CALC or SCYX?

Is CALC or SCYX more profitable?

Do institutionals & insiders believe in CALC or SCYX?

Which has more volatility and risk, CALC or SCYX?

Summary

How does CalciMedica compare to Clene?

Do institutionals and insiders have more ownership in CALC or CLNN?

Does the media refer more to CALC or CLNN?

Which has stronger valuation and earnings, CALC or CLNN?

Do analysts rate CALC or CLNN?

Which has more volatility & risk, CALC or CLNN?

Is CALC or CLNN more profitable?

Summary

How does CalciMedica compare to Agrify?

Do institutionals and insiders hold more shares of CALC or AGFY?

Is CALC or AGFY more profitable?

Which has more volatility and risk, CALC or AGFY?

Does the media favor CALC or AGFY?

Which has preferable valuation & earnings, CALC or AGFY?

Do analysts recommend CALC or AGFY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC vs. The Competition

CalciMedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools